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Demethylation by low-dose 5-aza-2′deoxycytidine impairs 3D melanoma
invasion partially through miR-199a-3p
expression revealing the role of this miR in
melanoma
Cécile Desjobert1†, Arnaud Carrier1†, Audrey Delmas2, Diego M. Marzese3, Antoine Daunay4, Florence Busato5,
Arnaud Pillon6, Jörg Tost5, Joëlle Riond1,7, Gilles Favre2, Chantal Etievant9 and Paola B. Arimondo1,8*

Abstract
Background: Efficient treatments against metastatic melanoma dissemination are still lacking. Here, we report that
low-cytotoxic concentrations of 5-aza-2′-deoxycytidine, a DNA demethylating agent, prevent in vitro 3D invasiveness of
metastatic melanoma cells and reduce lung metastasis formation in vivo.
Results: We unravelled that this beneficial effect is in part due to MIR-199A2 re-expression by promoter demethylation.
Alone, this miR showed an anti-invasive and anti-metastatic effect. Throughout integration of micro-RNA target prediction
databases with transcriptomic analysis after 5-aza-2′-deoxycytidine treatments, we found that miR-199a-3p downregulates
set of genes significantly involved in invasion/migration processes. In addition, analysis of data from melanoma patients
showed a stage- and tissue type-dependent modulation of MIR-199A2 expression by DNA methylation.
Conclusions: Thus, our data suggest that epigenetic- and/or miR-based therapeutic strategies can be relevant to limit
metastatic dissemination of melanoma.
Keywords: DNA methylation, microRNA, Melanoma aggressiveness, Epigenetics

Background
Cutaneous metastatic melanoma is the deadliest form of
skin cancer, with a 5-year survival rate particularly low (<
10%) and increasing incidence [1]. Until recently, patients
with metastatic melanoma had few treatment options, including surgery, radiation therapy and/or chemotherapy,
giving transient and limited results. Since 2011, new targeted therapies against mutated BRAF (vemurafenib) and
immunotherapies such as anti-CTLA4 (ipilimumab) and
anti-PD1/PD-L1 antibodies emerged, giving very promising long-term responses. Despite the efficacy of these
treatments in clinical trials, resistance rapidly arises after
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vemurafenib and immunotherapies can induce severe side
effects limiting the therapeutic response [2]. In addition,
not all patients respond to these therapies and no molecular marker is available to predict patient responsiveness to
immunomodulators. Therefore, there is still a strong need
for novel strategies.
Interestingly, targeting of the epigenetic regulation is
promising for the development of new anticancer treatments in solid tumours [3]. In the past few years, various
studies reported on epigenetic alterations in metastatic
melanoma, more specifically DNA methylation, and associated them with disease progression [4–9]. DNA methylation, catalysed by DNA methyltransferases (DNMT), is a
well-studied epigenetic change in cancer. In the last decade, several epigenetic drugs, such as DNA methylation
inhibitors (DNMTi), azacitidine (5aza, Vidaza®) and decitabine (5azadC, Dacogen™), have been approved for the
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treatment of haematological tumours. In solid tumours,
the use of epigenetic therapies is breaking through [10].
Hypomethylation of repetitive DNA elements and hypermethylation of CpG islands located in promoter regions of
specific genes are hallmarks of melanoma malignancy
[10–13]. Specific methylation signatures were also found
for melanoma tumours harbouring BRAF mutations [8,
14]. Thus, the use of an epigenetic strategy, combined
with relevant CpG island methylator phenotype (CIMP)
[15] as markers for the prediction of prognosis or therapeutic response, could be envisioned for metastatic melanoma treatment [10, 16, 17].
In this context, we investigated the implication of
DNA methylation in the aggressiveness of metastatic
melanoma and whether the use of demethylating agents
can reverse its invasive phenotype. We focused our attention on microRNAs (miRs), since these endogenous
non-coding RNAs of 19–25 nt can modulate the expression of several target genes via translational blockade
and/or transcript degradation and are broadly involved
in cancer progression. Furthermore, some miRs are described to be epigenetically regulated [12, 18] and to participate in the acquisition of invasive capabilities of
cancer cells, including melanoma [19–21]. Here, we
identified one specific hypermethylated miR gene,
MIR199A2, whose expression restoration by low doses
of 5-aza-2′-deoxycytidine or miR transfection impacts
on in vitro cell invasiveness and in vivo metastatic
formation.

Results
5azadC impairs melanoma cell invasiveness in a 3D
invasion model at low non-cytotoxic doses

To date, a limited number of studies have been published depicting the effects of DNMTi on metastatic
melanoma aggressiveness and most of them used 2D
culture conditions to study invasiveness [22–24], at the
exception of the study in combination with IFN-1 [25].
We set up a spheroid invasion assay to explore 3D invasive capacities of metastatic melanoma cells, since this
model better preserves cellular features such as cell
morphology and cell-cell and cell-extracellular matrix
adhesion, known to be important for metastatic dissemination [26]. The metastatic melanoma WM-266-4 cell
line constitutively expressing GFP (called herein
WM-266-4 GFP) was used to follow the 3D cell invasion. Non-treated and 5azadC-treated WM-266-4-GFP
cells were plated to form spheroids, which were embedded in collagen and monitored 24 h afterwards by fluorescent microscopy (Fig. 1a). Prior to measuring its effect
on 3D cell invasion, the cell sensitivity to daily treatments of 5azadC, the reference DNMTi, was tested during 3 days. The WM-266-4 GFP cell line displayed a
similar viability dose-response curve to the parental cell
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line WM-266-4, with an EC50 of 100 nM at 7 days (Additional file 1: Figure S2A). In addition, cell sensitivity to
5azadC resulted unchanged under different culture conditions, as shown by comparing 2D and 3D cultured
cells (Additional file 1: Figure S2B).
Hence, low concentrations of 5azadC, inducing little cell
death and inhibition of cell proliferation (EC50 = 100 nM),
were chosen for the 3D invasion assay to limit
non-specific cytotoxic effects and favour an epigenetic effect. As illustrated in Fig. 1b, c, 5azadC induced a
dose-dependent inhibition of 3D cell invasion, with a significant decrease of the invasion index starting at 3.2 nM
(P value < 0.001). The anti-metabolic compound cytarabine (araC), structurally similar to 5azadC and commonly
used in chemotherapies [27], was used as control at concentrations resulting in < 10% of cell death (1 nM, Additional file 1: Figure S3A). Unlike 5azadC, at the
equi-cytotoxic concentration, araC did not cause cell invasion inhibition (Additional file 1: Figure S3B and S3C),
confirming a different mechanism of action for 5azadC.
Next, the DNA demethylating activity of the drug was
determined by following the global DNA methylation level
in spheroids recovered before inclusion in collagen (at day
7, Fig. 1a). The methylation of four CpG sites in LINE-1
elements was chosen as a surrogate marker for global genomic DNA methylation [28]. Figure 1d shows that LINE-1
methylation decreased significantly upon treatment with
5azadC concentrations as low as 1 nM (P value < 0.05).
This demethylating effect was dose-dependent up to the
EC50 measured at day 7 (100 nM).
Altogether, our data revealed that 5azadC displays an
anti-invasive effect in a 3D metastatic melanoma model at
low concentrations. This effect is correlated to its DNA
demethylating action but not to its anti-metabolic and cytotoxic properties, as deduced from lack of effect of araC.
DNA methylation modulation by 5azadC reactivates miR199a-3p

To shed light on the mechanisms involved in the
5azadC-associated anti-invasive effect, we searched for
genes and in particular miRs that were hypermethylated
in the metastatic cell line WM-266-4 and which expression could be restored by promoter demethylation. Using
data from a genome-wide DNA methylation analysis
(BeadChip Illumina 450 K, data not shown), we compared
the methylation profile of WM-266-4 (metastatic cells)
and its non-invasive counterpart WM-115 cell lines (derived from the primary tumour of the same patient). All
genes and miR hypermethylated in WM-266-4 cell line
with a difference of at least 20% on three CpGs were selected. Among the 68 hypermethylated miRs, two were
chosen for further analysis since they were previously described as playing a role in cell invasion/migration processes: MIR-155HG [29] and MIR-199A2 [30, 31].
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Fig. 1 Effect of 5azadC on 3D invasion properties, DNA methylation and specific miR expression in WM-266-4 GFP cells. a Experimental scheme for
spheroid invasion assays. b Six spheroids were analysed for each 5azadC concentration as indicated. Photos shown in a are representative of one
spheroid per condition. c Histogram representing the mean invasion index (invasion area/spheroid initial area) calculated for 18 spheroids. d Mean
methylation percentage for five CpG sites in LINE-1 sequences. e Specific MIR-155HG and MIR-199A2 promoter demethylation was evaluated on
spheroids after 5azadC treatment. Median methylation of all the CpG sites is represented. f RT-qPCR analysis of mature miR-155, miR-199a-3p and miR199a-5p. The relative quantity (RQ) was calculated using RNU6B gene as control. All experiments were performed in triplicate. SEM are shown and *P
value < 0.05, **P value < 0.01, ***P value < 0.001. NS not significant

The methylation status of CpG sites in the promoter
of these two miRs was examined after 5azadC treatment
by DNA bisulfite conversion followed by pyrosequencing. For MIR-155HG, CpG sites were found hypermethylated in the non-treated WM-266-4 GFP spheroids with
a median methylation of 88% (Fig. 1e). Upon 5azadC

treatment, the decrease of methylation was comprised
between 10 and 23%. For the MIR-199A2 promoter,
CpG sites were found methylated at 73% in non-treated
WM-266-4 GFP spheroids and started to be demethylated from 1 nM of 5azadC. A maximum demethylation
of 31% was reached at 100 nM (Fig. 1e).

Fig. 2 Effect of miR overexpression on 3D metastatic melanoma cell invasion. a MiR-155, miR-199a-3p and miR-199a-5p were individually transfected, at
the indicated concentration, in WM-266-4 GFP cells 48 h before spheroid formation. Images shown are representative of one spheroid per condition. The
mean invasion index and SEM of two independent experiments are shown. b Top panel: main experimental steps for 5azadC treatments and anti-miR199a-3p transfection before performing the 3D-invasion assay. Representative images of spheroids for each condition and invasion index quantification are
presented. The mean index for 12 spheroids and SEM are shown. *P value < 0.05, **P value < 0.01, ***P value < 0.001, ND not determined, Ctl control and
NT not treated
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To correlate this DNA demethylation with the respective RNA expression, mature miR levels were monitored in
parallel. A dose-response increase of miR-155 expression
was found upon 5azadC treatment without statistical significance (Fig. 1f). Regarding miR-199a, two mature miR
species are known to be derived from the miR-199a precursor: miR-199a-5p and miR-199a-3p, the former being
13 times less expressed than the latter (Fig. 1f, RQ to
RNU6B of 0.086 ± 0.023 vs. 1.16 ± 0.14). A significant
RNA re-expression of nearly threefold was found with
100 nM of 5azadC for miR-199a-3p, while no significant
difference was observed for miR-199a-5p (Fig. 1f).
Hence, these results showed that low concentrations
of 5azadC lead to DNA demethylation of specific hypermethylated miR promoters in metastatic melanoma
WM-266-4 GFP cells. More specifically, MIR-199A2
promoter demethylation was correlated with the
re-expression of its mature form miR-199a-3p.
MiR-199a-3p impairs melanoma cell invasiveness and is
involved in the anti-invasive effect of 5azadC

Next, the effect of miR-199a-3p re-expression was evaluated in the metastatic melanoma 3D invasion assay. A
miR-199a-3p mimetic was transiently expressed in
WM-266-4 GFP cells 48 h before spheroid formation
(Fig. 2). A non-relevant miR (miR Ctl), miR-155 and
miR-199a-5p were used as controls (Fig. 2a and Additional file 1: Figure S4A). MiR-155 induced a cytotoxic
effect starting from low concentrations (5 nM), as
already described by Levati et al. [32]. A drastic reduction of cell invasion was found at very low concentrations of miR-199a-3p (Fig. 2a). This anti-invasive effect
started from 0.25 nM and reached a maximum at 1 nM
(P value < 0.001). It was specific to this miR, since its
complementary counterpart, miR-199a-5p, did not induce such a decrease of the invasion index (Fig. 2a).
These observations demonstrated that miR-199a-3p
alone was able to suppress the 3D invasion ability of
WM-266-4 GFP cells, suggesting that its re-expression
induced by DNA demethylation can contribute to the
anti-invasive effect of 5azadC.
To confirm this hypothesis, miR-199a-3p expression
was knocked down in 5azadC-treated cells using a specific anti-miR-199a-3p (Fig. 2b and Additional file 1: Figure S4B). The 3D anti-invasive ability of 5azadC was
significantly reduced, and the invasion index was partially restored (Fig. 2b). These findings support our hypothesis that miR-199a-3p plays a role in the
5azadC-mediated anti-invasive effect.
MET targeting by miR-199a-3p is not sufficient to affect
3D cell invasion

To better understand the role of miR-199a-3p in the invasion process, the combination of bioinformatics and

Fig. 3 MET as a potential target of miR-199a-3p in WM-266-4 cells. a
Relative expression of miR-199a-3p, DNMT1, EZH2, MET and COX2 in nonmetastatic WM-115 and metastatic WM-266-4 GFP cell lines. Results are the
mean of quadruplicates. MET mRNA and protein levels were measured
upon miR-199a-3p ectopic expression (b) and 5azadC treatment (c). “Tox”
indicates more than 50% of cytotoxicity. Histograms for mRNA expression
are the mean of at least triplicates normalised to their respective control
condition. For Western blots, one representative experiment out of three is
shown. Densitometric measurements of MET expression were normalised
to actin and relative to the control condition. d MET mRNA expression was
monitored in WM-266-4 GFP cells, transfected with a siRNA targeting MET
(siMET) at the indicated concentrations, by RT-qPCR (left panel) before
testing cells for 3D invasion (right panel). The mean invasion index is
calculated as previously and represented as histograms. SEM are shown. *P
value < 0.05, **P value < 0.01, ***P value < 0.001. Ctl control and NT
not treated

bibliographic approaches was used to identify its target
genes. Among the 41 validated mRNAs targets, retrieved
in the miRWalk database (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), ten were related to the
Gene Ontology (GO) terms of cell motion, cell migration and motility according to DAVID bioinformatics
tool [33] (Table S2). In particular, two were already described to be highly expressed in melanomas and
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Fig. 4 Deregulated pathways and candidate target genes of miR-199a-3p. a Transcriptomic analysis of WM-266-4 GFP cells transfected with miR199a-3p identified differentially expressed genes with a FC > 1.5. Heatmaps represented all deregulated genes for the two conditions (0.25 and
0.5 nM of miR-199a-3p). P value cutoff is FDR corrected. b Venn-diagram of all downregulated genes with a FC > 1.5 for miR-199a-3p-transfected
cells (812 genes), crossed with its predicted targets (common to five different softwares). The table summarises the 13 retrieved genes. Genes in
bold were further analysed. c CD2AP, FOS, ITGB8, NEDD4, SERPINE2 and VAMP3 expression in WM-266-4 cells transfected with miR-199a-3p or
treated with 5azadC. The mean fold inhibition was calculated as the ratio of RQ in treated cells/RQ in the control for each gene. SEM are shown
for triplicates. *P value < 0.05, **P value < 0.01. NS not significant

involved in the regulation of cell invasion: PTGS2, also
known as COX2 [34], and MET oncogene [30]. In
addition, we chose to study two major epigenetic regulators, DNMT1 (DNA methyltransferase 1) and EZH2 (enhancer of zeste homologue 2), since high levels of
expression have been associated to melanoma aggressiveness [35]. As shown in Fig. 3a, expression levels of
miR-199a-3p was significantly lower in the metastatic
WM-266-4 cell line compared to the primary WM-115,
while expression of DNMT1, EZH2 and MET were significantly higher and no significant differences were observed in the expression of COX2 mRNA (Fig. 3a). The
higher expression of DNMT1 and EZH2 is concordant
with previous observations in BRAF-mutated cells, such
as it is the case for WM266-4, described to participate
in the hypermethylated phenotype of metastatic melanoma cells ([36] and personal observations). In our
model, miR-199a-3p ectopic expression, at concentrations inducing an anti-invasive effect (Fig. 2a), did not

affect DNMT1, EZH2 and COX2 expression (Fig. 3a),
but led to the decrease of MET mRNA and protein
(Fig. 3a, b).
These results suggest an inverse relationship between
miR-199a-3p and MET and thus a possible direct targeting
of this oncogene by the miR. A similar decrease of MET
was also observed upon 5azadC treatment (Fig. 3c),
prompting us to hypothesise that re-expression of
miR-199a-3p following DNA demethylation participates in
the downregulation of MET. Nevertheless, MET knock
down was not sufficient to inhibit 3D invasiveness of metastatic melanoma as shown in Fig. 3d. Therefore, MET depletion seemed not to be the major event leading to
miR-199a-3p or 5azadC anti-invasive effect in our model.
MiR-199a-3p and 5azadC deregulate common genes
involved in invasion/migration pathways

To identify other genes targeted by miR-199a-3p and involved in invasion processes, we compared global gene
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Fig. 5 Schematic representation of common downregulated genes by miR-199a-3p and 5azadC. Genes predicted as targets of miR-199a-3p and
commonly downregulated by miR-199a-3p and 5azadC are highlighted in bold. ECM extracellular matrix, MMP matrix metalloproteinase, VAMP3
vesicle-associated membrane protein 3, CD2AP CD2-associated protein, CP capping protein, SERPINE2 serine protease inhibitor nexin 2

expression in miR-199a-3p vs control miR transiently
transfected cells by transcriptomic microarrays. The differential gene expression analysis, using a fold change
threshold > 1.5 and a P value < 0.05 (Fig. 4a), revealed
812 downregulated genes.
Genes that were downregulated upon miR-199a-3p transfection were crossed with gene list of its predicted targets
genes by five different softwares (DIANAmT, miRanda,
miRDB, miRWalk and TargetScan) on the website: http://
zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/ (as detailed
in the Additional file 1). Among 170, thirteen genes were retrieved (Fig. 4b). Six of them, CD2AP, FOS, ITGB8, NEDD4,
SERPINE2 and VAMP3 (highlighted in bold), belong to
cell-signalling or cell migration/adhesion pathways and were
chosen for further validation. The ectopic expression of
miR-199a-3p reduced their expression at the mRNA levels
with fold changes ranging from 1.5 to 8 (Fig. 4c). Noteworthy, five out of these genes were also downregulated
upon 5azadC treatment (Fig. 4c). CD2AP is a membrane
scaffold protein that has a role in dynamic actin assembly
and lamellipodia formation. ITGB8, a β-integrin, connects
adhesive proteins in the ECM to the intracellular actin cytoskeleton mediating cell adhesion and migration. SERPINE2,
a member of the serine protease inhibitor nexin superfamily,
contributes to the invasion in solid tumours and more specifically in colorectal cancers bearing KRAS or BRAF mutations [37]. VAMP3, an endosomal SNARE protein, is
involved in vesicular trafficking and exocytosis of matrix metalloproteinases MMP2 and MMP9 and β-integrins that are

required for cell motility. Finally, FOS forms heterodimers
with JUN to reconstitute the transcription regulator AP-1,
which participates in skin tumour development by controlling a wide range of cellular processes, including cell migration. Altogether, these results highlighted that 5azadC and
miR-199a-3p impact on metastatic melanoma invasion properties by downregulating common effectors of this multistep
biological process. Figure 5 schematically summarises the
possible interplay between the four proteins, CD2AP, ITGB8,
SERPINE2 and VAMP3, in the cell migration process, based
on the data in the literature.
Both 5azadC and miR-199a-3p alone impair lung
metastasis formation by WM-266-4 cells in vivo

To test the anti-tumour effect of 5azadC and miR-199a-3p,
in vivo experiments were performed using a melanoma
model for metastasis formation in the lungs (Fig. 6a). SCID
mice were injected in the tail vein with WM-266-4 cells
previously treated with 100 nM 5azadC or transfected with
0.5 or 1 nM of miR-199a-3p, compared to non-treated or
miR-Ctl-transfected cells, respectively. Lungs were collected
21 days after the injection, and metastasis numbers and
area were counted after tyrosinase staining (Fig. 6a). A significant reduction of both parameters was observed upon
5azadC treatment (Fig. 6b). A similar anti-metastatic effect
was observed with miR-199a-3p, despite a higher observed
heterogeneity (Fig. 6c). These in vivo experiments validate
miR-199a-3p as an anti-tumour effector and the potential
interest of re-expressing this miR or using the
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Fig. 6 In vivo effect of 5azadC and miR-199-3p expression on WM-266-4 lung metastasis. a Experimental outline: WM-266-4 cells treated or not with
100 nM of 5azadC for 3 days or transfected with miR-199-3p mimetic at 0.5 or 1 nM for 48 h were injected in the tail vein (IV) of SCID mice. Lungs were
recovered for immunohistochemical analysis 21 days after injection. b A representative image of the stained lung is shown for each group. Plots
representing the percentage area and the total number of metastasis on one slice for each mouse in non-treated (NT) and 5azadC-treated are shown
for two independent experiments. Medians are shown. c Same as in B for miR Ctl and miR-199-3p tested at two concentrations, 0.5 and 1 nM. **P value
< 0.01, ***P value < 0.001

demethylating drug 5azadC to limit metastasis formation in
melanoma cells presenting a hypermethylated MIR-199A2.
Promoter methylation status and expression of MIR199A2 in patient samples

To further validate the importance of MIR-199A2 DNA
methylation in human melanoma progression, we analysed The Cancer Genome Atlas (TCGA) RNA-seq and

DNA methylation datasets available for skin cutaneous
melanoma (SKCM) tumours on the UCSC cancer genomics browser website. In Fig. 7a, DNA methylation
levels of the MIR-199A2 promoter were compared according to the tumour site location. This locus was
found significantly (P value < 0.01) less methylated in
the regional cutaneous tissues (RCT) than the primary
tumours (PT) of the cohort, while an increase in its
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Fig. 7 Patient sample analysis and schematic representation of the role of miR-199-3p in melanoma aggressiveness. a DNA methylation level of six
consecutive CpG sites in the genomic vicinity of MIR199A2 gene. TCGA SCKM data was classified according to the melanoma tissue type. b microRNA199A2 expression according to melanoma tissue types. c DNA methylation of Mir-199A2 were analysed in formaldehyde-fixated samples from 12 PT,
15 LN and 16 DM (10 bowel and 6 liver) samples. Median methylation of all the CpG sites is represented. d Schematic representation of MIR199A
promoter methylation and expression as a function of the clinical stages. Blue arrows indicate a decrease in the DNA methylation and red arrows an
increase. Green arrows indicate a decrease in the miR expression and red arrows an increase

methylation was observed in the regional lymph nodes
metastases (LNM) in comparison to the RCT (P value <
0.05). Consistently, the expression of miR-199a was
found increased in the RCT, where it was less methylated, and decreased in the LNM and distant organ metastases (DOM), where it was more methylated (P value
< 0.01; Fig. 7b). We then confirmed these data on a cohort of 43 melanoma patients (Fig. 7c). These observations suggested that this locus is submitted to a
tight epigenetic modulation during melanoma progression (Fig. 7d): demethylation at local stages
(RCT), methylation and decreased expression at
stages that start to disseminate (LN) and maintained
at DMs. In summary, these data confirm that
MIR-199A2 is regulated by DNA methylation of its
promoter in patients and this methylation varies according to the disease stages. In addition, we observed that the MIR-199A2 promoter is commonly
methylated in cells derived from patients bearing the
most aggressive forms of the tumour compared to
the primary counterparts with few exceptions
(Additional file 1: Figure S5).
Taken together, these data support our hypothesis that
MIR-199A2 hypermethylation can be important at an

early stage for the acquisition of an invasive phenotype
by the melanoma tumour cells.

Discussion
Epigenetic therapies are very promising strategies to fight
cancer, since epigenetic modifications are reversible and can
be chemically modulated. In particular, promoters’ demethylation by 5-azaC or 5-azadC induces the re-expression of several genes or miRs in cancer cells inducing an anti-cancer
effect [27]. To date, few clinical trials using epigenetic drugs
have been conducted in metastatic melanoma; a recent example is the combination of 5azadC and temozolomide [38,
39]. Yet, epigenetic modifications and, in particular, genomic
hypermethylation of CpG islands and miR modulation were
shown to sign metastatic melanoma progression [40, 41].
To the best of our knowledge, few reports explored
the impact of 5azadC on the cellular mechanism involved in metastatic melanoma, particularly on cell invasiveness, and its potential use as an anti-metastatic drug
[23]. To address this question and better mimic the
tumour behaviour in vivo, we developed a 3D cell invasion assay using spheroids embedded in a matrix of collagen I, the principal component of the extracellular
matrix (ECM). Growing evidence showed that cancer
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cell spheroids reproduce various traits of micro-tumours, thus providing a better model for assessing
tumour invasion [26]. Using the metastatic melanoma
WM-266-4 GFP cell line, we showed for the first time
that low-cytotoxic concentrations of 5azadC inhibit 3D
cell invasion in vitro. In addition, this effect was clearly
associated with a global and promoter-specific DNA demethylation. These observations are in complete agreement with Rajaii et al.’s results on uveal melanoma cells,
describing that low concentrations of 5azadC reduced
both 2D invasion and clonogenicity [23]. Our results in
metastatic melanoma cells confirm also the anti-cancer
potential of using low doses of the DNA demethylating
agents in solid tumours as for haematological cancers
[27, 38, 42].
To further elucidate the mechanisms underlying the
phenotypical changes induced by 5azadC, we specifically
investigated the modifications on miR methylation and
expression. MiRs are post-transcriptional regulators that
have a broad spectrum of cellular regulation by targeting
multiple genes and pathways, including those required
for metastatic melanoma progression like cell invasion
and migration (reviews [40]). Moreover, their expression
or DNA methylation signatures are studied as reliable
markers for diagnosis and prognosis of cancer [10].
Here, two miRs, MIR-155HG and MIR-199A2, implicated in migration and invasion processes, were found
hypermethylated in the metastatic melanoma cell line
(WM-266-4) compared to its primary counterpart
(WM-115). MiR-155 is an important multi-functional
miR involved in the development of multiple solid tumours and is transcriptionally regulated by DNA methylation [29]. However, 5azadC-induced demethylation of
MIR-155HG promoter (> 20%) was not sufficient to significantly reactivate miR-155 expression in our metastatic melanoma cell model. Moreover, its ectopic
re-expression in the WM-266-4 cells induced a cytotoxic
effect rather than an anti-invasive effect. Thus, we focused on MIR-199A2 that was found hypermethylated in
the WM-266-4 cell line and both demethylated and
reactivated by 5azadC.
Few reports identified epigenetically modulated miRs in
melanomas (reviews [40, 41]). For the first time, we report
that MIR-199A2 locus is under epigenetic regulation in a
metastatic melanoma model and it is reactivated by promoter demethylation by 5azadC. In addition, nanomolar
concentrations of miR-199a-3p impairs 3D cell invasion,
unlike miR-199a-5p. Furthermore, the anti-invasive effect
of 5azadC was counterbalanced by a specific antago-miR
suggesting that miR-199a-3p takes part of the
anti-invasive response induced by 5azadC. Importantly,
the transient expression of miR-199a-3p in WM-266-4
cells reduced significantly their metastatic potency in vivo,
supporting an anti-cancer effect of this miR.
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These results are somewhat contradictory to those reported by Pencheva et al. (2012) [43], describing that the
cooperation between three miRs, miR-199a-3p,
miR-199a-5p and miR-1908, promoted metastasis by
impairing two proteins, APOE and DNAJA4, involved in
tumour cell invasion and in angiogenesis. This discrepancy can be explained as follows. First, the cellular
models used are significantly different. Pencheva et al.
selected for their study the most in vivo metastatic subclones of MeWo and A375, two metastatic melanoma
cell lines bearing BRAF wild-type and BRAFV600E mutation, respectively. These subclones overexpressed
miR-199a-3p and miR-199a-5p in different proportions.
The A375 subclones, bearing a mutated BRAF, as it is
the case of the WM266-4 cell line, overexpressed much
higher levels of miR-199a-5p (× 10,000) than of
miR-199a-3p (× 10), strongly suggesting that mainly the
miR-199a-5p supported the pro-metastatic effect that
was observed by the authors in these subclones. In
agreement with this hypothesis, we observed a reversion
of the anti-invasive effect of miR-199a-3p when combined with increasing amounts of the complementary
miR-199a-5p mimetic (data not shown), revealing a
sponge effect of the latter. Second, Pencheva et al. performed in vivo experiments with the combination of the
three
LNA
anti-miRs,
targeting
miR-199a-3p,
miR-199a-5p and miR-1908 but not with individual ones
or the miR-199a-3p mimetic alone. Thus, it cannot be
excluded that the balance between each miR level can
affect the tumour development. Moreover, cumulative
evidences have shown that miR-199a has important but
versatile functions in tumourigenesis depending on the
nature and the stage of the cancer [31]. Indeed, Yang et
al. found that low expression levels of miR-199a-5p in
tumour melanoma tissue samples from patients were associated to the advances of tumour stage [44]. Their observations in B16 melanoma cells and in tumour
xenografts seem to indicate that miR-199a-5p is a
tumour suppressor, via direct targeting of HIF-1α. Third,
our findings in metastatic melanoma are in agreement
with an increasing number of observations in other cancer types. In testicular tumour, MIR-199A2 hypermethylation was linked to malignancy progression [45]. In this
model, miR-199a re-expression led to the suppression of
cell growth, cancer migration, invasion and metastasis in
vitro and in vivo. Similar observations were made in
non-small cell lung cancer, colorectal cancer and breast
cancer cell lines [46]. A tumour-suppressive role of this
miR was also demonstrated in papillary thyroid carcinoma, in which miR-199a-3p was shown to be likely regulated by the BRAFV600E oncogene [47]. Similar
anti-cancer functions were described in renal cell carcinoma [48], endometrial carcinoma [49] and prostate
cancer [50].
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Finally, to better understand the mechanisms involved
in the miR-199a-3p-mediated anti-invasive effect in
metastatic melanoma, its target genes were investigated.
The proto-oncogene MET was found overexpressed in
the metastatic vs. primary cell line. Despite its downregulation by both miR-199a-3p and 5azadC, its specific inhibition was not sufficient to impair 3D metastatic
melanoma invasion (Fig. 4). Next, by a transcriptomic
and bioinformatic approach, we observed that
miR-199a-3p targeted several genes involved in key
pathways for cell migration/invasion. This alteration of
multiple targets can better explain the in vitro
anti-invasive and in vivo anti-metastatic effects of the
miR. Interestingly, 5azadC also downregulated common
effectors of this multistep biological process (Fig. 5). In
addition, analysis of TCGA SKCM datasets supports a
tight modulation of MIR-199A2 promoter methylation
and miR-199a expression during melanoma progression,
with local stages (RCT) presenting a promoter demethylation and an increased expression, whereas disseminated
tumours (LN) show a MIR-199A2 hypermethylation
concomitant to a decreased repression (Fig. 7). These
observations were further confirmed on an experimental
cohort of primary melanoma, lymph node and distant
metastasis. Altogether, these observations can explain
the different effects found in the literature for
miR-199a-3p depending on its targets and strongly promote the interest of its reactivation at early melanoma
stages that start to locally disseminate.

Conclusions
In conclusion, we proved that slightly cytotoxic doses of
5azadC are translated into an anti-invasive effect in a
BRAF-mutated metastatic melanoma model. This effect
is in part associated with MIR-199A2 promoter demethylation and re-expression of its specific mature form
miR-199a-3p. Indeed, this miR on its own impairs 3D
cell invasion by simultaneously targeting multiple genes
involved in adhesion/migration processes. This effect
was further confirmed in an in vivo xenograft model
with transiently transfected cells, thus supporting its implication in metastatic melanoma aggressiveness. Finally,
the clinical relevance of our results is confirmed by the
analysis of the TCGA cancer skin cohort and 43 patient
samples, showing that MIR-199A2 promoter methylation
and expression is finely tuned during melanoma progression. Hypermethylation of its promoter was found
associated with LN metastasis stages before distant dissemination (Fig. 7), suggesting its expression extinction
could be involved in metastasis progression. Taken together, our findings support the use of epigenetic drugs
or miR mimetic-based therapeutic strategies, either
alone or in combination, for limiting metastatic dissemination of melanomas. Concordantly, a combination of
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5azadC with temozolomide was recently investigated in
a phase I/II trial and proven to be safe and improve response and overall survival rates [38].

Materials and methods
The details of the protocols, including primer sequences,
are reported in Additional file 1.
Human cell lines

The WM-115 and WM-266-4 cell lines were purchased
from the European Collection of Authenticated Cell Culture (ECACC), were subjected to cell line authentication
via short tandem repeat profiling and were grown up to a
maximum of 20 passages and for fewer than 6 months following resuscitation in our laboratory. The WM-266-4
GFP cell line was obtained by transduction with WPXLd,
a lentiviral vector encoding GFP, and selected by flow cytometry. Additionally, four primary melanoma cell lines
(WC00060, WC00062, WC0008 and WC00081) were purchased from the Coriell Cell Repository (Coriell Institute
for Medical Research, Camden, NJ, USA).
Drug treatments

5-Aza-2′-deoxycytidine (5azadC, decitabine) and cytarabine (araC) from Sigma-Aldrich (St Louis, USA) were
dissolved in water at 10 mM and frozen at − 20 °C until
use. Serial dilutions were made in culture media and
added on cells seeded 24 h earlier at a density of 0.6 ×
105 cells/mL in a 12-well plate. Treatment was repeated
during 3 days, and cells were harvested at day 4 for further analysis.
Cell viability assay

The half effective concentration (EC50) of 5azadC or
araC was determined at day 7 after the first treatment
on WM-266-4 GFP cells using ATP-lite™ assay (Perkin
Elmer, France) according to the manufacturer for cells
cultured in 2D conditions. This protocol was also
adapted for spheroids (3D conditions).
3D cell invasion assay

WM-266-4 GFP (3000 cells/well) were allowed to form
spheroids for 2 days on agarose 1% (Sigma-Aldrich,
#A95–39) coated in 96-well plates, leading to ~
300-μm-diameter spheroids. Then, six different spheroids for each condition were individually embedded in
EMEM media (Lonza, #BE12-684F) containing 1% of
Bovine Collagen I (BD, #354231) and 2% SVF. The initial
spheroid size (day 7) and the 24-h invasion area (day 8)
were measured by fluorescent microscopy, using an
Axiovert 200 M device (5X Plan-Neofluor objective, Carl
Zeiss, Germany). Fluorescent invasion areas were quantified using ImageJ (NIH) software on the sum of six
Z-stacks images (20-μm interval) for each spheroid.
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Invasion index was obtained by normalising the invasion
area at 24 h by the initial spheroid area: invasion area/
spheroid area (Additional file 1: Figure S1). Six individual spheroids were quantified for each condition, and
three independent experiments were performed.
Genomic DNA purification

Paraffin-embedded tissue sections were microdissected,
and DNA was purified using the ZR FFPE DNA MiniPrep (Zymo Research, Irvine, CA) as reported [51]. Genomic DNA from melanoma cell lines was extracted
using DNAzol reagent (Life Technologies, Carlsbad, CA)
as in [7].
Bisulfite modification and pyrosequencing

Quantitative DNA methylation analysis was performed
by pyrosequencing of bisulfite-treated DNA as described
in [52]. Two PCR were carried out for the five CpGs of
interest on the miR-199a-3p locus.
PCR1: (1 CpG):
Forward: TTAGGGGTTGTATTTAGTTTTTTTT
Reverse: Biotine-ATTCATTACCAATTCCCCAATCTA
Pyrosequencing primer: GGTTGTGATTTTTAGTTTT
GAYGTGGT
PCR2: (4 CpGs):
Forward: Biotine-GTTATTTTGGGGAGGTTTGGGTAT
G
Reverse: CCCACTTCCTACCCAATTAAAAAAAA
Pyrosequencing primer:
CCATTTTATACACAAACCCATATCTAAAA
ACAAACRATTCTAACRATCTCTCCAACRACAC
AACRCATA
Microarray expression and GO terms analysis

RNA samples were extracted from cells transfected with
miR-199a-3p miR mimetic as described in Additional file 1. Experiments were performed in three biological replicates for each condition and analysed on
Affymetrix Human Gene 2.0 ST arrays. RMA normalisation was applied, and genes differentially expressed between treated and control conditions were determined
choosing a threshold of log2 fold change at 0.5 and a P
value < 0.05. P value cutoff is FDR corrected [53]. Significantly enriched pathways were chosen using a threshold enrichment score > 2. Data have been submitted to
the Gene Expression Omnibus database.
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Germain-sur-l’Arbresle, France) were injected into the
tail vein with 3 × 106 viable WM-266-4 cells in 200-μL
PBS, previously treated or not with 5azadC at 100 nM
(3 × 3 days) or transfected with miR negative control #1
(miR Ctl) or miR-199a-3p mimic at 0.5 or 1 nM during
48 h. Each group constituted of 4–5 mice. For 5azadC
treatment, two independent experiments were performed. Twenty-one days after injection, mice were dissected and lungs recovered, formalin fixed and paraffin
embedded. Sections were stained with haematoxylin and
eosin (H&E). The number and area of macrometastasis
were measured in total lung sections by immunostaining
with Tyrosinase antibody Mob299–05 (1/500) (Diagnostic BioSystem, Pleasanton, CA-USA) on an Aperio
Scanner (Leica) with Tissue Studio software (Definiens,
Munich, Switzerland) for automatic segmentation and
quantification of lesions. Statistics were performed using
the Mann-Whitney test.
The Cancer Genome Atlas skin cutaneous melanoma
(TCGA-SKCM) dataset analysis

The TCGA-SKCM DNA methylation, RNA-sequencing
(RNAseq) and clinical datasets were accessed in June
2016. Wilcoxon-Mann-Whitney test was applied to determine the significance of DNA methylation or gene expression differences between primary and metastatic
melanoma tissues.
Melanoma patients included in the study

Melanoma patients and healthy individuals were included in the study under protocols approved by the
Western institutional review board. Informed consent
was obtained from all subjects, and the experiments
were performed according to the principles set out in
the WMA Declaration of Helsinki and the NIH Belmont
Report. Tissue specimens were coded according to
HIPAA recommendations to ensure the confidentiality
of the patients. The specimen cohort included
paraffin-embedded tissues including nevi (NEV; n = 7),
primary melanomas (PRM; n = 16), lymph node metastases (LNM; n = 15) and distant organ metastases (DOM;
n = 20). Additionally, cell lines derived from LNM (n =
11) were established at JWCI and included in the study.
For each patient, median DNA methylation was calculated on five CpGs on the miR-199a-3p locus.

Additional file
In vivo metastasis experiments

The animals were handled and cared for in accordance
with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and European
Directive EEC/86/609, under the supervision of the
authorised investigators. Un-anesthetised 7-week-old female SCID mice (Charles River Laboratories, Saint-

Additional file 1: Table S1. Target sequences, PCR and sequencing
primers used for pyrosequencing assays. Figure S1. Measurement of the
invasion index. Figure S2. Cytotoxic effect of 5azadC on WM-266-4 and
WM-266-4 GFP cells. Figure S3. Comparison of araC and 5azadC effects
on cell viability and 3D invasion. Figure S4. MiRNA expression levels after
transfection. Figure S5 (A) Mir-199A2 CpG methylation in cell lines. B) RTqPCR analysis of mature miR-199a-3p in cell lines. (DOCX 1759 kb)
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